Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xinshumu
- Development stage
- Unknown
- Lead developer
- Xi'an Xintong Pharmaceutical Research
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Xinshumu is a first-in-class, liver-targeted small molecule drug developed for the treatment of chronic hepatitis B. It is the first Class 1 innovative drug approved in Shaanxi province, China, and represents a significant advancement in hepatitis B therapy. Xinshumu utilizes the HepDirect liver-targeted prodrug delivery system to concentrate its active metabolic components specifically in the liver, thereby enhancing efficacy and reducing systemic toxicity. Clinical data from Phase III trials demonstrate that Xinshumu offers robust antiviral efficacy with a superior safety profile compared to existing therapies, particularly benefiting patients with low viral loads. Its mechanism allows for improved durability of response over time relative to current standard-of-care treatments[1].
- Brand names
- xinshumu
- Other names
- previver mesylate tablets
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on xinshumu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xinshumu.